155 related articles for article (PubMed ID: 19814747)
41. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study.
Park JW; Park KW; Cho SH; Park HS; Lee WJ; Lee DH; Kim CM
Am J Gastroenterol; 2005 Oct; 100(10):2194-200. PubMed ID: 16181368
[TBL] [Abstract][Full Text] [Related]
42. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
43. A Danish nationwide questionnaire study of hepatitis B virus screening before immunosuppressive therapy.
Bunyoz KI; Krarup H; Weis N
Dan Med J; 2017 Mar; 64(3):. PubMed ID: 28260595
[TBL] [Abstract][Full Text] [Related]
44. [Investigation of hemodialysis patients in terms of the presence of occult hepatitis B].
Altindiş M; Uslan I; Cetinkaya Z; Yüksel S; Ciftçi IH; Demirtürk N; Ozdemir M; Arslan F; Aktepe OC
Mikrobiyol Bul; 2007 Apr; 41(2):227-33. PubMed ID: 17682709
[TBL] [Abstract][Full Text] [Related]
45. Family physicians' knowledge and screening of chronic hepatitis and liver cancer.
Ferrante JM; Winston DG; Chen PH; de la Torre AN
Fam Med; 2008 May; 40(5):345-51. PubMed ID: 18465284
[TBL] [Abstract][Full Text] [Related]
46. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab.
Miyagawa M; Minami M; Fujii K; Sendo R; Mori K; Shimizu D; Nakajima T; Yasui K; Itoh Y; Taniwaki M; Okanoue T; Yoshikawa T
J Med Virol; 2008 Dec; 80(12):2069-78. PubMed ID: 19040281
[TBL] [Abstract][Full Text] [Related]
47. Dermatologists' awareness of and screening practices for hepatitis B virus infection before initiating tumor necrosis factor-α inhibitor therapy.
Stine JG; Bass M; Ibrahim D; Khokhar OS; Lewis JH
South Med J; 2011 Dec; 104(12):781-8. PubMed ID: 22089354
[TBL] [Abstract][Full Text] [Related]
48. Does hepatitis C virus affect the reactivation of hepatitis B virus following renal transplantation?
Yen TH; Huang CC; Lin HH; Huang JY; Tian YC; Yang CW; Wu MS; Fang JT; Yu CC; Chiang YJ; Chu SH
Nephrol Dial Transplant; 2006 Apr; 21(4):1046-52. PubMed ID: 16390851
[TBL] [Abstract][Full Text] [Related]
49. Hepatitis B reactivation in allogeneic hemopoietic stem cell transplantation setting: a pediatric experience.
Faraci M; Cappelli B; Lanino E; Morreale G; Fioredda F; Giudice CL; Giacchino R
Pediatr Transplant; 2009 Nov; 13(7):923-6. PubMed ID: 19032422
[TBL] [Abstract][Full Text] [Related]
50. [Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab].
Mimura N; Kojima H; Tsujimura H; Ise M; Sakai C; Fukai K; Yokosuka O; Kumagai K
Rinsho Ketsueki; 2010 Mar; 51(3):213-5. PubMed ID: 20379117
[TBL] [Abstract][Full Text] [Related]
51. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients.
Squadrito G; Pollicino T; Cacciola I; Caccamo G; Villari D; La Masa T; Restuccia T; Cucinotta E; Scisca C; Magazzu D; Raimondo G
Cancer; 2006 Mar; 106(6):1326-30. PubMed ID: 16453330
[TBL] [Abstract][Full Text] [Related]
52. Fulminant hepatitis after allogenic bone marrow transplantation caused by reactivation of hepatitis B virus with gene mutations in the core promotor region.
Kitano K; Kobayashi H; Hanamura M; Furuta K; Ueno M; Rokuhara A; Tanaka E; Umemura T; Kiyosawa K
Eur J Haematol; 2006 Sep; 77(3):255-8. PubMed ID: 16923112
[TBL] [Abstract][Full Text] [Related]
53. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
Endo T; Sakai T; Fujimoto K; Yamamoto S; Takashima H; Haseyama Y; Nishio M; Koizumi K; Koike T; Sawada K
Bone Marrow Transplant; 2001 Feb; 27(4):433-6. PubMed ID: 11313673
[TBL] [Abstract][Full Text] [Related]
54. [German guidelines on diagnosis and therapy of hepatitis B].
Wedemeyer H; Cornberg M; Protzer U; Berg T; Dollinger MM
Dtsch Med Wochenschr; 2007 Aug; 132(34-35):1775-82. PubMed ID: 17713890
[TBL] [Abstract][Full Text] [Related]
55. Poor recognition of risk factors for hepatitis B by physicians prescribing immunosuppressive therapy: a call for universal rather than risk-based screening.
Visram A; Chan KK; McGee P; Boro J; Hicks LK; Feld JJ
PLoS One; 2015; 10(4):e0120749. PubMed ID: 25875198
[TBL] [Abstract][Full Text] [Related]
56. Practice Patterns in Hepatitis B Virus Screening Before Cancer Chemotherapy in a Major US Hospital Network.
Kwak YE; Stein SM; Lim JK
Dig Dis Sci; 2018 Jan; 63(1):61-71. PubMed ID: 29177849
[TBL] [Abstract][Full Text] [Related]
57. [Risk Management of HBV Reactivation: Construction of Check System].
Tanaka Y
Rinsho Byori; 2015 Sep; 63(9):1052-9. PubMed ID: 26731893
[TBL] [Abstract][Full Text] [Related]
58. Hepatitis B and cancer: A practical guide for the oncologist.
Bozza C; Cinausero M; Iacono D; Puglisi F
Crit Rev Oncol Hematol; 2016 Feb; 98():137-46. PubMed ID: 26657667
[TBL] [Abstract][Full Text] [Related]
59. Analysis of medical prescribing practices for hepatitis B serology tests.
Girard A; Moreau-Gaudry A; Alpes Réseau P; Hilleret MN
Gastroenterol Clin Biol; 2010 Jan; 34(1):8-15. PubMed ID: 19836914
[TBL] [Abstract][Full Text] [Related]
60. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.
Wong WW; Hicks LK; Tu HA; Pritchard KI; Krahn MD; Feld JJ; Chan KK
Breast Cancer Res Treat; 2015 Jun; 151(3):639-52. PubMed ID: 25962692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
